Body mass index as a prognostic feature in operable breast cancer:: the International Breast Cancer Study Group experience
Body mass index as a prognostic feature in operable breast cancer:: the International Breast Cancer Study Group experience
复制标题
DOI：
10.1093/annonc/mdh222
复制
发表时间：
2004-06-01
影响因子：
50.5
通讯作者：
International Breast Cancer Study Grp
中科院分区：
文献类型：
--
作者：
Berclaz, G;Li, S;International Breast Cancer Study Grp
背景：目前关于体重指数 (BNH) 对早期乳腺癌患者预后重要性的信息基于各种模棱两可的报告。很少有关于 BMI 与全身治疗相关的数据。 患者和方法：患者 (6792) 被随机分配参加 1978 年至 1993 年的国际乳腺癌研究组试验，研究化疗和内分泌治疗。 BMI还通过其他八个因素进行评估：绝经状态、淋巴结状态、雌激素受体状态、孕激素受体状态、肿瘤大小、血管侵犯、肿瘤分级和治疗。 BMI分为正常（小于或等于24.9）、中等（25.0-29.9）或肥胖（大于或等于30.0）。结果：在调整其他因素的成对比较中，BMI正常的患者总生存期（OS）和无病生存期（DFS）明显长于BMI中等或肥胖的患者。亚组分析显示，绝经前和围绝经期患者以及仅接受化疗的患者具有相同的效果。当进行整体评估并调整其他因素时，BMI 显着影响 OS (P = 0.03)，但不影响 DFS (P = 0. 12)。结论：BMI 是乳腺癌患者 OS 的独立预后因素，特别是在未接受内分泌治疗的化疗前/围绝经期患者中。
Background: Current information on the prognostic importance of body mass index (BNH) for patients with early breast cancer is based on a variety of equivocal reports. Few have data on BMI in relationship to systemic treatment.Patients and methods: Patients (6792) were randomized to International Breast Cancer Study Group trials from 1978 to 1993, studying chemotherapy and endocrine therapy. BMI was evaluated with eight other factors: menopausal status, nodal status, estrogen receptor status, progesterone receptor status, tumor size, vessel invasion, tumor grade and treatment. BMI was categorized as normal (less than or equal to24.9), intermediate (25.0-29.9) or obese (greater than or equal to30.0).Results: Patients with normal BMI had significantly longer overall survival (OS) and disease-free survival (DFS) than patients with intermediate or obese BMI in pairwise comparisons adjusted for other factors. Subset analyses showed the same effect in pre- and perimenopausal patients and in those receiving chemotherapy alone. When assessed globally and adjusted for other factors, BMI significantly influenced OS (P = 0.03) but not DFS (P = 0. 12). \Conclusions: BMI is an independent prognostic factor for OS in patients with breast cancer, especially among pre-/perimenopausal patients treated with chemotherapy without endocrine therapy.